MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Evolus Long-Term Debt 2011-2026 | EOLS
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Evolus
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122 M | 4.81 M | 1.22 M | 2.26 M | 40.5 M | 91.5 M | 16.9 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 122 M | 1.22 M | 39.8 M |
Quarterly Long-Term Debt Evolus
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 146 M | 145 M | 122 M | 122 M | 121 M | 121 M | 121 M | 4.81 M | 95.1 M | 94.8 M | 72 M | 1.22 M | 71.7 M | - | 71.4 M | 2.26 M | 2.49 M | 2.71 M | 2.94 M | 3.15 M | 133 M | 74.2 M | 73.8 M | 73.5 M | 73.2 M | 72.9 M | 73.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 146 M | 1.22 M | 72.9 M |
Long-Term Debt of other stocks in the Drug manufacturers industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
256 K | - | - | $ 142 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
343 K | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
21.8 M | - | - | $ 754 M | USA |
 |
Cronos Group
CRON
|
4.27 M | $ 2.66 | -0.56 % | $ 1.4 B |  Canada |
 |
Canopy Growth Corporation
CGC
|
300 M | $ 1.28 | 7.8 % | $ 138 M | Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
5.01 M | - | 7.5 % | $ 6.35 M | USA |
 |
Agile Therapeutics
AGRX
|
1.52 M | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
4.86 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
16.7 M | - | - | $ 50.1 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
24.1 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
29 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Eagle Pharmaceuticals
EGRX
|
56.2 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
8.15 B | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
446 M | $ 13.4 | -3.67 % | $ 686 M | USA |
 |
Evoke Pharma
EVOK
|
5 M | - | - | $ 36.6 M | USA |
 |
Athenex
ATNX
|
93 K | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
1.12 M | $ 21.48 | -0.09 % | $ 2.04 B |  France |
 |
Sundial Growers
SNDL
|
16.2 M | $ 1.65 | -0.3 % | $ 3.37 M | Canada |
 |
Harrow Health
HROW
|
247 M | $ 50.59 | -0.81 % | $ 1.65 B | USA |
 |
China Pharma Holdings
CPHI
|
39.9 K | $ 1.39 | 2.21 % | $ 24.3 M |  China |
 |
Jupiter Wellness
JUPW
|
114 K | - | - | $ 33.6 M | USA |
 |
OrganiGram Holdings
OGI
|
104 M | $ 1.74 | 3.57 % | $ 402 M | Canada |
 |
Bausch Health Companies
BHC
|
21.9 B | $ 7.81 | -1.2 % | $ 2.85 B | Canada |
 |
Lannett Company
LCI
|
615 M | - | 1.15 % | $ 7.11 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
4.94 M | $ 4.78 | -7.96 % | $ 67.2 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
65 K | - | - | $ 193 M | Canada |
 |
Aurora Cannabis
ACB
|
295 M | $ 4.25 | 0.12 % | $ 86.3 M | Canada |
 |
Organogenesis Holdings
ORGO
|
718 K | $ 4.25 | -1.28 % | $ 560 M | USA |
 |
Pacira BioSciences
PCRX
|
585 M | $ 26.09 | 0.35 % | $ 1.21 B | USA |
 |
PetIQ
PETQ
|
438 M | - | 1.64 % | $ 400 M | USA |
 |
Perrigo Company plc
PRGO
|
3.58 B | $ 14.84 | 1.64 % | $ 2.04 B | USA |
 |
ProPhase Labs
PRPH
|
2.4 M | - | - | $ 5.07 M | USA |
 |
Recro Pharma
REPH
|
339 K | - | -4.76 % | $ 65.3 M | USA |
 |
Radius Health
RDUS
|
315 K | - | - | $ 1.42 B | USA |
 |
Rockwell Medical
RMTI
|
8.29 M | $ 1.0 | 4.65 % | $ 23.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
2.66 M | $ 4.4 | 1.85 % | $ 132 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
27 K | $ 3.82 | 1.33 % | $ 4.74 M | USA |
 |
OptiNose
OPTN
|
611 K | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
38.5 M | $ 9.4 | -0.32 % | $ 668 M | USA |
 |
PLx Pharma
PLXP
|
622 K | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
1.23 M | $ 5.32 | -5.17 % | $ 217 M | USA |
 |
Tilray
TLRY
|
221 M | $ 9.13 | 1.57 % | $ 5.64 B | Canada |
 |
SCYNEXIS
SCYX
|
2.58 M | $ 0.67 | 3.96 % | $ 32.1 M | USA |
 |
Tricida
TCDA
|
11.3 M | - | - | $ 3.25 M | USA |
 |
Veru
VERU
|
2.92 M | $ 2.32 | -2.11 % | $ 313 M | USA |
 |
TherapeuticsMD
TXMD
|
6.53 M | $ 2.01 | -1.62 % | $ 21 M | USA |
 |
cbdMD
YCBD
|
2.4 M | $ 1.1 | - | $ 4.74 M | USA |
 |
Viatris
VTRS
|
18 B | $ 12.61 | 1.16 % | $ 15.3 B | USA |
 |
Zomedica Corp.
ZOM
|
1.81 M | - | -0.21 % | $ 98 M | USA |